Mar, N., Petrylak, D. P., Hoimes, C. J., Rosenberg, J. E., Flaig, T. W., Gourdin, T. S., Barata, P. C., Henry, E., Bilen, M. A., George, S., Rao, S., Assikis, V. J., Burgess, E. F., Lewis, B. E., Srinivas, S., Gorla, S. R., Meng, C., Zhu, Y., O'Donnell, P. H. (2025). Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4583